Hospitalisation, complications, raise treatment cost of type 2 diabetes

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1539, 2006-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insulin use, disease complications raise costs in type 2 DM

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 429, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus

By Ward Alexandra O’Brien Judith A Salas Maribel

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

Dapagliflozin for the treatment of type 2 diabetes

By Abdul-Ghani Muhammad A DeFronzo Ralph A

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1695-1703

Informa Healthcare

Access to resources Recommend Favorite

Thiazolidinediones in the treatment of Type 2 diabetes

By Greenberg Andrew S Pittas Anastassios G

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 529-540

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin for the treatment of type 2 diabetes

By Del Prato Stefano

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 17, 2011-12 ,pp. : 2759-2762

Informa Healthcare

Access to resources Recommend Favorite